Keyphrases
Chemotherapy
61%
High-dose Chemotherapy
47%
Breast Cancer Patients
44%
Overall Survival
42%
Phase II Trial
32%
Cisplatin
30%
Breast Cancer
30%
Capecitabine
29%
Doxorubicin
27%
Recurrence Score
26%
Paclitaxel
25%
Advanced Breast Cancer
25%
Cancer Patients
24%
Hepatocellular Carcinoma
24%
Human Epidermal Growth Factor Receptor 2 (HER2)
24%
Progression-free Survival
23%
Tumor
23%
Patients with Breast Cancer
23%
Placebo
22%
Early Breast Cancer
21%
Bevacizumab
21%
Systematic Meta-analysis
20%
Hormone Receptor-positive
19%
Metastatic Breast Cancer
19%
Meta-analysis
19%
Cyclophosphamide
19%
Hazard Ratio
19%
Confidence Interval
18%
Malignancy
17%
Marrow
16%
Chemotherapy-induced
16%
Oncology
16%
Letrozole
15%
Clinical Outcomes
15%
Adverse Events
15%
Vascular Toxicity
14%
Liver
14%
Gemcitabine
14%
Fertility Preservation
14%
Trastuzumab
14%
Dose-dense Chemotherapy
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Ribociclib
13%
Pembrolizumab
13%
Granulocyte Colony-stimulating Factor (G-CSF)
13%
Hematopoietic Stem Cells
13%
Pancreatic Cancer
13%
Breast Cancer Recurrence
12%
A3 Adenosine Receptor
12%
Allogeneic Bone Marrow Transplantation
12%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Chemotherapy
90%
Malignant Neoplasm
62%
Overall Survival
44%
Neoplasm
41%
Capecitabine
29%
Diseases
29%
Progression Free Survival
28%
Placebo
25%
Cisplatin
24%
Paclitaxel
24%
Epidermal Growth Factor Receptor
24%
Metastatic Breast Cancer
23%
Liver Cell Carcinoma
23%
Recurrent Disease
21%
Hormone Receptor
21%
Bevacizumab
21%
Pancreas Cancer
21%
Cyclophosphamide
19%
Adverse Event
19%
Doxorubicin
19%
Namodenoson
17%
High Dose Chemotherapy
16%
Rash
15%
Phase III Trials
14%
Gamma Urogastrone
14%
Letrozole
14%
Trastuzumab
14%
Clinical Trial
13%
Epidermal Growth Factor Receptor 2
11%
Carmustine
11%
Letrozole Plus Ribociclib
10%
Prospective Study
10%
Solid Malignant Neoplasm
10%
Nanocapsule
10%
Gemcitabine
10%
Pembrolizumab
10%
Taxane
10%
Randomized Controlled Trial
9%
Colorectal Carcinoma
9%
Ovary Insufficiency
9%
Dyspnea
9%
Fluorouracil
9%
Infection
9%
Cetuximab
8%
Protein Tyrosine Kinase Inhibitor
8%
Ovary Cancer
8%
Diarrhea
8%
Adenosine A3 Receptor Agonist
8%
Erlotinib
8%
Medicine and Dentistry
Breast Cancer
99%
Malignant Neoplasm
57%
Overall Survival
39%
Neoplasm
37%
Diseases
28%
Placebo
28%
High Dose Chemotherapy
28%
Recurrent Disease
26%
Cancer
26%
Progression Free Survival
24%
Oncology
22%
Doxorubicin
20%
Hormone Receptor
20%
Hepatocellular Carcinoma
18%
Pancreas Cancer
18%
Radiation Therapy
17%
Health Care Cost
15%
Arm
15%
Adverse Event
15%
Capecitabine
15%
Infection
14%
Fertility Preservation
14%
Systematic Review
13%
Phase III Trials
13%
Pembrolizumab
13%
Clinical Trial
13%
Hematopoietic Cell
13%
Gamma Urogastrone
13%
Epidermal Growth Factor Receptor 2
13%
Letrozole
12%
Olaparib
11%
Gemcitabine
10%
Meta-Analysis
10%
Germ Cell
10%
Dose Densification
10%
Letrozole Plus Ribociclib
10%
Advanced Cancer
10%
Cisplatin
9%
Quality of Life
9%
Ovary Insufficiency
9%
Colorectal Carcinoma
9%
Hazard Ratio
8%
BRCA Mutation
8%
Trastuzumab
8%
Ovarian Reserve
8%
Breast Carcinoma
8%
Oocyte
8%
Blood Flow
8%
Liver Metastasis
8%
Metastatic Breast Cancer
7%